Longbo Wang

Longbo advises biotechnology companies on structuring and negotiating complex commercial transactions, including license agreements, strategic collaborations, drug discovery agreements, and manufacturing and supply agreements.

His recent transactions include representing:

• A biotechnology company with a machine learning-guided antibody discovery and development platform in relation to a strategic collaboration with a Fortune 500 biopharmaceutical company to advance artificial intelligence-driven antibody therapeutics*

• A clinical-stage biopharmaceutical company in relation to a multiyear, multi-target strategic collaboration agreement with a global biotechnology company to advance a new class of medicines for use in cancer treatment*

• A China-based, publicly traded biopharmaceutical company in relation to the out-licensing of a potential first-in-class antibody drug conjugate to a biopharmaceutical company*

• A biotechnology company in relation to an exclusive license with a China-based biopharmaceutical company to commercialize its “minibody” (an antibody fragment) in the Greater China market*

• A biopharmaceutical company in a collaboration and licensing agreement with a biopharmaceutical oncology company to out-license a breakthrough bispecific antibody for development and commercialization in the US, Canada, Europe and Japan*

• A biopharmaceutical company in relation to an exclusive license agreement to commercialize its small-molecule medicine for cancer treatment in the European Economic Area, United Kingdom, Switzerland and Turkey*

• A clinical-stage biopharmaceutical company in relation to its strategic collaboration agreement with a China-based biopharmaceutical company for the development, manufacture and commercialization of its medicine in mainland China*

• A South Korea-based, clinical-stage, immune-oncology company in relation to an exclusive license agreement with a China-based biopharmaceutical company for the development, manufacture and commercialization of its monoclonal antibody in Greater China*

• A drug discovery company in relation to:
  • A license agreement with a cancer biotechnology company to research, develop, manufacture and sell worldwide a clinical-stage BRAF-inhibiting compound for the treatment of solid tumors*
  • A license agreement with a biotechnology company for worldwide rights to develop and commercialize a clinical-stage BRAF-inhibiting compound for the treatment of solid tumors*

• A leading biopharmaceutical company in China in relation to a license agreement with a South Korea-based biopharmaceutical company for the exclusive license for the development, regulatory approval and commercialization of a programmed cell death protein 1 (PD-1) monoclonal antibody in South Korea*

• A leading pharmaceutical company in South Korea in relation to its license agreement with a biopharmaceutical company for the global (excluding South Korea) rights to develop, manufacture and commercialize a small-molecule medicine*

* Representation handled before joining Cooley